Park Tae Young, Kang Hyun, Choi Geun Joo, Oh Hyoung-Chul
Division of Gastroenterology, Chung-Ang University College of Medicine, 102 Heukseok-ro Dongjak-gu, Seoul, Korea.
Department of Anesthesiology and Pain Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Surg Endosc. 2023 Feb;37(2):1366-1375. doi: 10.1007/s00464-022-09808-4. Epub 2022 Dec 12.
Randomized controlled trials (RCTs) have demonstrated that aggressive hydration with lactated Ringer's (LR) solution reduces the frequency and severity of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). In this trial sequential analysis (TSA), we aimed to evaluate the prophylactic effect of aggressive hydration on PEP in specific patient subgroups and to determine the need for additional RCTs.
We conducted a systematic and comprehensive search to identify all randomized controlled studies published through August 2021 that examined the effectiveness of aggressive hydration for preventing PEP. The primary outcome was the frequency of PEP. We also performed TSA to calculate the required information size and assess whether our results were conclusive.
The analysis included 12 studies involving 2,501 patients. According to the TSA, the overall frequency of PEP was significantly lower in the aggressive hydration group (5.6%; 74 of 1,327 patients) than in the control group (13.1%; 154 of 1,174 patients) (risk ratio [RR]: 0.458; 95% confidence interval [CI]: 0.350-0.599). In the subgroup analysis of patients with average risk, the cumulative Z curve crossed both the conventional test boundary and the trial sequential monitoring boundary. However, in the high-risk group and in patients with moderate-to-severe PEP, the Z curve did not cross the trial sequential monitoring boundary.
This TSA indicates that aggressive hydration is effective in the overall prevention of PEP. However, additional RCTs are required to examine the prophylactic effect of aggressive hydration with LR on PEP in high-risk populations.
随机对照试验(RCT)已证明,使用乳酸林格氏液(LR)进行积极补液可降低内镜逆行胰胆管造影术(ERCP)后胰腺炎(PEP)的发生率和严重程度。在本序贯分析(TSA)中,我们旨在评估积极补液对特定患者亚组中PEP的预防效果,并确定是否需要开展更多的随机对照试验。
我们进行了系统全面的检索,以识别截至2021年8月发表的所有研究积极补液预防PEP有效性的随机对照研究。主要结局是PEP的发生率。我们还进行了TSA以计算所需信息量,并评估我们的结果是否具有结论性。
该分析纳入了12项研究,涉及2501例患者。根据TSA,积极补液组中PEP的总体发生率(5.6%;1327例患者中有74例)显著低于对照组(13.1%;1174例患者中有154例)(风险比[RR]:0.458;95%置信区间[CI]:0.350-0.599)。在平均风险患者的亚组分析中,累积Z曲线越过了传统检验边界和序贯试验监测边界。然而,在高危组和中重度PEP患者中,Z曲线未越过序贯试验监测边界。
本TSA表明积极补液在总体预防PEP方面是有效的。然而,需要开展更多的随机对照试验来研究使用LR进行积极补液对高危人群PEP的预防效果。